Innoviva (NASDAQ:INVA) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Innoviva (NASDAQ:INVA) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. TheStreet upgraded shares of Innoviva from a c rating to a b- rating in a research report on Thursday, February 29th. StockNews.com upgraded shares of Innoviva from a hold rating to a buy rating in a research report on Friday, March 29th.

Innoviva Trading Up 0.4 %

Shares of Innoviva stock opened at $16.22 on Tuesday. Innoviva has a 12-month low of $12.22 and a 12-month high of $16.86. The company has a current ratio of 10.42, a quick ratio of 9.17 and a debt-to-equity ratio of 0.63. The stock has a market cap of $1.01 billion, a PE ratio of 7.31 and a beta of 0.58. The company has a 50-day moving average of $15.53 and a two-hundred day moving average of $15.59.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter. Innoviva had a net margin of 58.21% and a return on equity of 28.94%. The company had revenue of $77.50 million during the quarter.

Institutional Trading of Innoviva

Several large investors have recently modified their holdings of INVA. Texas Permanent School Fund Corp boosted its position in Innoviva by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 49,358 shares of the biotechnology company’s stock worth $752,000 after acquiring an additional 662 shares during the last quarter. SummerHaven Investment Management LLC boosted its position in Innoviva by 1.2% during the fourth quarter. SummerHaven Investment Management LLC now owns 58,298 shares of the biotechnology company’s stock worth $935,000 after acquiring an additional 705 shares during the last quarter. Profund Advisors LLC boosted its position in Innoviva by 7.9% during the third quarter. Profund Advisors LLC now owns 11,879 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 871 shares during the last quarter. ProShare Advisors LLC boosted its position in Innoviva by 6.2% during the first quarter. ProShare Advisors LLC now owns 16,150 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 942 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Innoviva by 13.2% during the fourth quarter. Quadrant Capital Group LLC now owns 9,042 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 1,056 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.